What BioReperia does

BioReperia AB is a Swedish preclinical oncology company founded in September 2015 by Anna Fahlgren and Lasse Jensen, based on zebrafish tumor xenograft technology developed at Linköping University. The company operates its ZTX (Zebrafish Tumor Xenograft) platform, which uses humanized zebrafish embryos as in-vivo hosts for patient-derived and cell-line-derived tumor xenografts, enabling evaluation of drug efficacy, metastasis inhibition, and immune oncology responses within five days. BioReperia commercializes the platform through two product lines: ZTX ONCOLEADS, a contract research service offering for biopharmaceutical companies, biotech firms, and academic institutions conducting preclinical oncology drug discovery (tumor efficacy, metastasis, immune oncology, toxicology, screening, disease modeling); and ZTX PREDICT, a CE-certified precision medicine diagnostic service for clinical healthcare providers that tests patient tumor biopsies to identify the most effective anti-cancer treatment within five days for clinical decision support. The clinical laboratory is ISO-13485 and ISO-15189 compliant.

The company generates revenue through quote-based professional services contracts — typically multi-year project engagements priced by scope, number of models, cell lines, and experimental endpoints — with named customers including CIS Biopharma AG, Noxopharm Ltd, Glycyx MOR Inc, ImmunoFyx, Cantargia AB, Charles River Laboratories, and Linköping University. Distribution is primarily direct enterprise sales, supplemented by a strategic channel partnership with Charles River Laboratories (which embeds the ZTX platform in CRL's global PDX Tumor Compendium offering) and a wholly-owned Swiss subsidiary established in December 2019 via Hemex AG incubator to serve the DACH region. BioReperia has raised a Series A funding round (~$830K, 2019) and participates in the EU H2020-MSCA-RISE consortium. The company is headquartered in Linköping, Sweden, with approximately 7-8 employees, and underwent a leadership transition in March 2026 appointing Emmelie Persson as CEO and Anna Erkstam as Chief Business Officer.

Name

BioReperia

Legal name

BioReperia AB

Website

https://bioreperia.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

BioReperia AB is a Swedish preclinical oncology CRO that uses its proprietary Zebrafish Tumor Xenograft (ZTX) platform to deliver in-vivo drug efficacy, metastasis, and immune oncology readouts to biopharma clients within five days, and offers a CE-certified ZTX PREDICT precision medicine diagnostic service to clinical oncology providers for individualized cancer treatment selection.

Ownership category

akta.pro rank

Product category

Preclinical Oncology Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Zebrafish xenograft models
• Preclinical oncology services
• Drug discovery CRO
• Precision medicine diagnostics
• Patient-derived xenograft research

Headquarters

HQ city

Linköping

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Services (CRO): BioReperia provides fee-for-service research contracts to pharmaceutical companies, biotech firms, and academic institutions. Services include tumor efficacy testing, metastasis evaluation, immune oncology studies, toxicology assessments, and disease model studies. Pricing is quote-based with project-specific scope.
2. Clinical Diagnostic Services (ZTX PREDICT): CE-certified diagnostic service for clinical providers that tests patient tumor biopsies to identify most effective cancer treatments within 5 days. Laboratory is ISO-13485 and ISO-15189 compliant. Provides treatment planning tool for clinical oncology.
3. Patient Stratification for Clinical Trials: Pharmaceutical companies use ZTX platform as inclusion criteria for clinical trials, testing patient tumor cells for sensitivity to specific treatments to identify responders and include only responsive patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

BioReperia provides contract research services using its proprietary Zebrafish Tumor Xenograft (ZTX) platform for preclinical oncology drug discovery and a CE-certified precision medicine diagnostic service. The biopharma offering (ZTX ONCOLEADS) evaluates tumor efficacy, metastasis, immune oncology, screening, toxicology, and disease models, delivering lead candidate selection in 5 days. The clinical offering (ZTX PREDICT) tests patient tumor biopsies to identify the most effective cancer treatment for individual patients within 5 days, serving pharmaceutical companies, biotech firms, academic institutions, and clinical healthcare providers.

Product overview

BioReperia offers a unified ZTX (Zebrafish Tumor Xenograft) platform with two distinct product lines: ZTX ONCOLEADS for drug discovery (biopharma/academia) and ZTX PREDICT for precision medicine (clinical providers/patients). The platform leverages zebrafish embryos as an in-vivo model system to evaluate drug efficacy, tumor regression, and metastasis inhibition within 5 days. Both products share the core ZTX technology but serve different market segments - ONCOLEADS accelerates preclinical drug development while PREDICT enables individualized cancer treatment selection. The platform is CE-certified for clinical use and complies with ISO-13485 and ISO-15189 standards.

Differentiator

Problem solved

Functional benefit

Brands

• ZTX PREDICT: A CE-certified Zebrafish Tumor Xenograft platform that identifies the most efficient anti-cancer drug for individual patients within 5 days, providing clinical decision support for pharmaceutical or surgical treatment.
• ZTX ONCOLEADS
• ZTX Platform

Products and services

• ZTX ONCOLEADS Humanized in-vivo oncology drug discovery platform that mimics the complex tumor environment using the proprietary ZTX zebrafish xenograft technology, enabling biopharmaceutical and academic clients to select the best lead candidates for further pharmaceutical development within 5 days. Used for preclinical drug efficacy, metastasis, immune oncology, screening, toxicology, and disease model studies.
• ZTX PREDICT CE-certified precision medicine diagnostic service that tests patient tumor biopsies in BioReperia's ISO-13485/ISO-15189 compliant laboratory to identify the most efficient anti-cancer drug for individual patients within 5 days, providing clinical decision support for pharmaceutical or surgical treatment selection and metastasis risk assessment. Services clinical healthcare providers and supports patient stratification for clinical trials.
• ZTX Platform (Parent Technology) The proprietary Zebrafish Tumor Xenograft (ZTX) platform providing in-vivo data on tumor regression and metastasis inhibition of compounds within 5 days, enabling rapid oncology drug screening and clinical decision support. The platform underpins both ZTX ONCOLEADS and ZTX PREDICT offerings, leveraging zebrafish embryos' transparency, undeveloped immune systems, and rapid vascularization.

Quantifiable outcome

• Treatment prediction accuracy of 80% compared to clinical outcomes
• +6 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Charles River LaboratoriescoreChannel Partner/ Reseller/ Distributor · 18 December 2019Strategic partnership where Charles River Laboratories provides access to their Tumor Compendium of over 1000 fully characterized PDX models. The ZTX platform supports all PDX models from Charles River, and collaborative studies have been presented at AACR conferences. The partnership enables pharmaceutical companies to screen PDX models using the zebrafish platform before mouse studies.
• InVivo BioSystemsminorStrategic or Co-development PartnerCo-hosted webinar on 'Advancing Human Disease Research with Zebrafish Models: From Tank to Bedside' with Joseph Bruckner, PhD from InVivo Biosystems. Partnership for knowledge sharing and cross-promotion in zebrafish model research.
• Inaphea BiolabsminorStrategic or Co-development PartnerPartner service provider offering advanced drug discovery services including biomarker analysis, disease modeling, and preclinical screening. Collaboration for joint service delivery and market expansion.
• Cantargia ABminorStrategic or Co-development PartnerCollaboration for pre-clinical evaluation of CAN04 antibody for lung and pancreatic cancer. AACR 2020 poster presentation showed synergistic effects of CAN04 with cisplatin, including anti-metastatic activity in cisplatin-resistant models.
• Mount SinaiminorStrategic or Co-development PartnerAcademic partner for co-hosted webinar on 'Advancing Prostate Cancer Targeted Therapy: Breakthroughs Using Zebrafish Tumor Xenograft Models' with Sujit Nair, PhD from Icahn School of Medicine at Mount Sinai.
• NEOGAP TherapeuticsminorStrategic or Co-development PartnerAcademic collaboration for evaluation of checkpoint inhibitors and autologous T cell activation on primary tumor tissue using zebrafish tumor xenograft models.
• Karolinska InstituteminorStrategic or Co-development PartnerAcademic collaboration contributing to AML study published in Leukemia journal, strengthening validation of DCPS as therapeutic target for acute myeloid leukemia.
• Region ÖstergötlandminorStrategic or Co-development PartnerRegional healthcare provider collaboration for ovarian cancer patient treatment planning using zebrafish tumor-derived xenograft models.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• WuXi AppTec: Global CRO/CDMO with comprehensive preclinical oncology and drug discovery services. Competes for the same biopharma preclinical budgets though with a much broader service portfolio.
• Charles River Laboratories: Global CRO with extensive preclinical oncology and PDX model offerings, and BioReperia's principal strategic channel partner for Tumor Compendium access. Comparable as an oncology preclinical services incumbent, though much broader in scope.
• Crown Bioscience (JSR Life Sciences): Global preclinical and translational CRO with a large PDX and oncology model portfolio. Comparable as a competitor for preclinical oncology drug discovery budgets at biopharma customers.
• Inotiv: Preclinical CRO with model development, toxicology, and translational research services, including oncology models. Comparable as a broad preclinical services competitor.

Emerging players

• InVivo BioSystems: Specialized zebrafish CRO offering in-vivo disease modeling and toxicology services. Direct competitor in zebrafish-based preclinical research and listed BioReperia partner.
• Inaphea Biolabs: Partner and emerging CRO offering biomarker analysis, disease modeling, and preclinical screening services, including zebrafish expertise. Comparable as a smaller emerging preclinical CRO with adjacent capabilities.
• Hera BioLabs: Specialized preclinical CRO with focus on patient-derived and humanized models for oncology and immuno-oncology drug development. Comparable emerging player in preclinical oncology CRO services.

Direct peers

• Champions Oncology: Specialized oncology CRO focused on patient-derived xenograft models, tumor profiling, and preclinical drug development. Closely comparable service offering for biopharma preclinical programs.
• ZeClinics: Zebrafish-focused CRO providing preclinical drug discovery, safety pharmacology, and toxicity services. Direct competitor in zebrafish-based CRO services for pharma and biotech.
• Phylonix Services: Early commercial zebrafish CRO offering in-vivo drug efficacy and toxicity assessments. Direct competitor in the same zebrafish preclinical services niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioReperia